Search and browse research peptide entries by compound name, pharmacologic class, or literature focus. Each profile summarizes published context and links to our cited roundups where available. Research Use Only — not for human or animal consumption.
BPC-157 is a synthetic pentadecapeptide sequence derived from gastric-juice protein fragments. It is among the most discussed catalog peptides in connective-tissue and gastrointestinal preclinical literature — with a large but investigator-concentrated rodent bibliography.
TB-500 commonly refers to a fragment or analog related to thymosin beta-4 actin-binding biology. Catalog naming is inconsistent — full-length Tβ4, fragments, and mislabeled products all appear in commerce.
GHK-Cu is the copper complex of a naturally occurring tripeptide studied across dermatology, wound-healing, and cosmetic science for decades. It is analytically tractable but frequently sold without adequate identity or copper-content documentation.
Semaglutide is a GLP-1 receptor agonist with extensive published human trial literature as an approved drug product. Catalog research peptide labeled semaglutide is a separate RUO material — not interchangeable with pharmaceutical formulations without verified identity and context.
Tirzepatide combines GIP and GLP-1 receptor agonism in a single acylated peptide — a distinct research object from GLP-1–selective molecules like semaglutide, with large published SURPASS and SURMOUNT trial programs.
Retatrutide is a development-stage triple agonist adding glucagon receptor activity to dual incretin pharmacology. Human data are earlier and narrower than for semaglutide or tirzepatide, with active phase 2 literature.
Cagrilintide is a long-acting amylin analog studied in combination with GLP-1 agonists in metabolic research programs. It extends the incretin research arc with amylin-pathway biology distinct from GLP-1 alone.
AOD-9604 is marketed as a fragment of human growth hormone associated with lipolytic research interest. Published literature is sparse relative to incretin peptides, and catalog identity verification is essential.
Ipamorelin is a selective growth hormone secretagogue studied for relatively narrow hormonal release profiles compared with first-generation GHRPs. It is frequently paired in research discussions with GHRH analogs such as CJC-1295.
CJC-1295 with DAC is a GHRH analog modified for extended exposure via albumin-binding chemistry. Pharmacokinetics differ substantially from the no-DAC form — they are separate research materials, not interchangeable vials.
The no-DAC form of CJC-1295 is a shorter-acting GHRH analog than the DAC-modified variant. Research discussions often pair it with ipamorelin or GHRP-class peptides — combination data remain predominantly preclinical.
GHRP-2 is a first-generation growth hormone releasing peptide characterized in 1990s secretagogue research. It remains a reference compound in comparative GH-axis pharmacology literature.
GHRP-6 was among the first synthetic GHRPs characterized in ghrelin receptor research. Rodent literature documents appetite-stimulating effects alongside GH release — distinguishing it from more selective later compounds.
Hexarelin is a potent hexapeptide ghrelin mimetic cited in GH-axis research and, separately, in rodent cardiac ischemia-reperfusion models. Cardioprotective preclinical findings do not establish clinical cardiac benefit.
Abaloparatide is an FDA-approved PTHrP analog studied in the ACTIVE phase 3 trial for postmenopausal osteoporosis. Sequence and signaling profile differ from teriparatide despite shared peptide length.
Adamax commonly refers to an N-acetylated Semax variant sold in research catalogs. Acetylation alters N-terminal charge and may affect stability and permeability in model systems — it is a distinct chemical entity from unmodified Semax.
Angiotensin (1-7) is a heptapeptide metabolite of the renin-angiotensin system studied as a counter-regulatory arm opposing Ang II signaling, with cardiovascular and fibrosis research literature.
Argireline is a widely used acetylated hexapeptide in cosmetic dermatology research, marketed as a topical SNAP-25 mimetic. It is among the most cited cosmetic peptides in formulation literature.
B7-33 is a minimized relaxin-2 analog designed as a biased RXFP1 agonist with anti-fibrotic activity in rodent organ models. Not FDA-approved; distinct from native two-chain relaxin.
Cartalax is an Ala-Glu-Asp tripeptide bioregulator discussed in cartilage and connective-tissue aging research. It shares sequence motifs with other Khavinson tetrapeptides but is a distinct catalog entity requiring explicit identity proof.
CGRP is a sensory neuropeptide central to migraine pathophysiology research and the target of multiple approved therapeutics. Native α-CGRP and β-CGRP isoforms differ by three residues — catalog material must specify which sequence is supplied.
Copper peptides refer to a class of copper-binding sequences — chiefly GHK-Cu — studied in dermatology, wound healing, and matrix biology. This library entry covers the class; see the dedicated GHK-Cu roundup for the primary reference compound.
Cortagen is an Ala-Glu-Asp-His tetrapeptide bioregulator studied in adrenal cortex and stress-axis aging research. It is among the organ-targeted Khavinson peptides where catalog naming and sequence confirmation matter.
Dihexa is a synthetic oligopeptide developed as a small-molecule mimetic of hepatocyte growth factor signaling. Preclinical literature emphasizes synaptogenesis and cognitive endpoints in rodent models — with no established human clinical program for catalog material.
DSIP is a nine-residue peptide originally isolated from rabbit brain and associated with sleep-induction research dating to the 1970s. Human and animal studies report mixed, often modest effects on sleep and stress biomarkers — with replication gaps across decades.
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) associated with telomerase and pineal-aging research from the Khavinson bioregulator literature. Catalog material is analytically simple but requires batch identity confirmation.
Exenatide is the first-in-class GLP-1 receptor agonist based on exendin-4 from Gila monster venom, with long-standing human trial literature. It anchors incretin research history before later acylated analogs like liraglutide and semaglutide.
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt FOXO4–p53 interactions in senescent cells. It sits at the intersection of senolytic research and catalog peptide supply, where sequence fidelity is critical.
Glutathione is the central intracellular tripeptide antioxidant studied across redox biology, detoxification, and aging research. Catalog supply includes reduced (GSH) and oxidized (GSSG) forms requiring explicit specification.
Humanin is a 24-amino-acid peptide first identified in surviving neurons of Alzheimer's disease tissue. It is studied for cytoprotective, metabolic, and inflammatory endpoints across mitochondrial peptide research.
IGF-1 LR3 is an engineered IGF-1 analog with an Arg3 substitution and N-terminal extension that evades IGFBP sequestration. Widely used in cell culture and rodent research; no FDA approval and WADA-prohibited.
KPV is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone studied in gut inflammation, skin inflammation, and immune-modulation research. Small size makes identity testing straightforward when documentation is provided.
Liraglutide is an earlier-generation acylated GLP-1 receptor agonist with extensive published trial literature as an approved drug. Catalog research peptide labeled liraglutide is separate RUO material requiring full acylation verification.
LL-37 is the sole human cathelicidin peptide, cleaved from hCAP-18 and studied across innate immunity, wound healing, and inflammatory signaling. Catalog material requires sequence confirmation for the full 37-mer.
Mazdutide is a dual GLP-1 and glucagon receptor agonist in active clinical development, studied in obesity and type 2 diabetes research programs. Evidence maturity is earlier than for semaglutide or tirzepatide.
Melanotan II is a synthetic cyclic heptapeptide melanocortin agonist studied in melanogenesis, pigmentation, and central melanocortin signaling research. It is chemically related to bremelanotide (PT-141) but is not an FDA-approved drug product.
MGF in literature refers to IGF-1Ec, an IGF-1 splice variant up-regulated after muscle stress. Catalog MGF usually means a synthetic 24-mer E-peptide — not proven as an isolated endogenous product.
MOTS-c is a 16-residue peptide encoded within mitochondrial 12S rRNA, studied for metabolic regulation and exercise-mimetic effects in rodent models. Endogenous production and exogenous supply are distinct research contexts.
N-acetyl Selank amidate applies N-terminal acetylation and C-terminal amidation to the Selank heptapeptide sequence. Catalog listings treat it as a stabilized Selank derivative, but peer-reviewed literature on this exact modified sequence is thinner than for parent Selank.
N-acetyl Semax amidate combines N-terminal acetylation with C-terminal amidation on the Semax heptapeptide backbone. Both modifications are common medicinal-chemistry strategies for peptide stability — the result is a chemically distinct research material from Semax and Adamax.
Ovagen is a Glu-Asp-Leu tetrapeptide bioregulator associated with liver and hepatocyte aging research in the Khavinson literature. Catalog supply should be verified as the defined tetrapeptide, not an undisclosed liver extract.
Oxytocin is among the best-studied neuropeptides in neuroscience and endocrinology, with approved pharmaceutical formulations for defined obstetric indications and a vast experimental literature on social cognition — categories that should not be conflated with catalog RUO material.
P21 is a synthetic peptide derived from ciliary neurotrophic factor (CNTF) sequence logic, studied in preclinical models of neurogenesis and cognitive recovery after brain injury. Catalog naming overlaps with unrelated cell-cycle terminology — sequence confirmation is essential.
PEG-MGF is a pegylated synthetic MGF E-domain peptide engineered for extended half-life. It does not exist endogenously; most systemic MGF animal data use pegylated rather than native peptide.
Pinealon is a Glu-Asp-Arg tripeptide bioregulator studied in neuroprotective and brain-aging research from the Khavinson literature. It is analytically tractable but often sold without adequate batch characterization.
PNC-27 is a synthetic peptide derived from p53 sequence elements, studied in preclinical oncology models for selective cytotoxicity against certain transformed cell lines. Evidence is predominantly in vitro and early animal work.
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist derived from melanocortin peptide chemistry. It has published phase 3 clinical literature for central sexual-arousal pathways and is FDA-approved as Vyleesi — distinct from catalog RUO material without pharmaceutical documentation.
Selank is a synthetic heptapeptide derived from tuftsin with an added Gly-Pro C-terminal extension. Russian and Western literature describes anxiolytic-like effects in rodent models without classical benzodiazepine sedation, plus immunomodulatory research angles.
Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment developed in Russian neuropharmacology programs. Western-indexed literature explores neurotrophic gene expression, BDNF-related signaling, and neuroprotection in rodent models.
Sermorelin is the classical GHRH(1-29) analog with FDA approval history for pediatric GH deficiency (Geref, withdrawn commercially). Short half-life distinguishes it from tesamorelin and DAC-modified CJC-1295.
Snap-8 is an acetylated octapeptide studied in cosmetic science as a SNAP-25–related neuromuscular signaling modulator in topical formulation research. Evidence is predominantly in vitro and short-term cosmetic studies.
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide studied in mitochondrial dysfunction, heart failure, and rare disease research programs with published clinical-stage data — distinct from most catalog-only longevity peptides.
Survodutide is a dual GLP-1/glucagon receptor agonist studied in metabolic and MASH (NAFLD/NASH) research trials. Human data are phase 2–stage, narrower than established incretin drugs.
Teriparatide is FDA-approved PTH(1-34) for high-risk osteoporosis. Fracture Prevention Trial data established vertebral and nonvertebral fracture reduction — a formal clinical tier distinct from catalog repair peptides.
Tesamorelin is an FDA-approved GHRH analog studied in phase 3 trials for HIV-associated lipodystrophy with excess visceral adipose tissue. Catalog material is a distinct RUO supply chain from pharmaceutical Egrifta.
Thymalin refers to a thymus-derived peptide bioregulator preparation studied in immune aging and thymic involution research. Catalog products vary between defined peptides and complex extracts — identity scope must be explicit.
Thymosin alpha-1 is a 28-amino-acid thymic peptide with decades of immunology research and formal clinical programs in some jurisdictions. Catalog material is not interchangeable with approved drug presentations without verified identity.
Thymosin beta-4 is the full-length actin-binding protein underlying TB-500 fragment commerce. Phase 2 wound and corneal trials exist; catalog fragments require separate sequence confirmation.
Vesugen is a Lys-Glu-Asp tripeptide bioregulator studied in vascular and endothelial aging research from the Khavinson catalog. It is frequently discussed alongside cardiovascular recovery peptides but occupies a separate evidence base.
VIP is a widely distributed neuropeptide with extensive formal research in immunology, circadian biology, and neuroprotection. It is analytically well characterized but sensitive to oxidation and proteolysis — material handling matters as much as sequence identity.
Ziconotide is a marine-derived conopeptide approved as an intrathecal analgesic for severe chronic pain — a rare example of a catalog-discussed peptide with full regulatory approval under defined administration constraints. RUO supply is not the approved drug product.
Community content — not medical advice. Research use only; nothing here is instruction for human use.
We use strictly necessary cookies to run the site (your sign-in session and this choice). With your consent we also use analytics cookies to improve the site. See our Cookie Policy and Privacy Policy.